Flufenamic acid, COX inhibitor (ab120354)
Key features and details
- NSAID. COX inhibitor, channel blocker.
- CAS Number: 530-78-9
- Soluble in DMSO to 100 mM and in ethanol to 100 mM
- Form / State: Solid
- Source: Synthetic
Overview
-
Product name
Flufenamic acid, COX inhibitor -
Description
NSAID. COX inhibitor, channel blocker. -
Biological description
Non-steroidal anti-inflammatory. Potently inhibits human transthyretin amyloid fibril formation. Alters ion fluxes through the plasma membrane. Potent non-specific blocker of cation and anion channels, commonly used to block currents through TRP channels and receptor-operated channels.
-
CAS Number
530-78-9 -
Chemical structure
Properties
-
Chemical name
2-[3-(Trifluoromethyl)phenylamino]benzoic acid -
Molecular weight
281.23 -
Molecular formula
C14H10F3NO2 -
PubChem identifier
3371 -
Storage instructions
Store at Room Temperature. The product can be stored for up to 12 months. -
Solubility overview
Soluble in DMSO to 100 mM and in ethanol to 100 mM -
Handling
Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20°C. Generally, these will be useable for up to one month. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.
Toxic, refer to SDS for further information.
Need more advice on solubility, usage and handling? Please visit our frequently asked questions (FAQ) page for more details.
-
SMILES
FC(F)(F)c1cc(ccc1)Nc2ccccc2C(=O)O -
Source
Synthetic
-
Research areas
- Epigenetics and Nuclear Signaling
- Nuclear Signaling Pathways
- Nuclear Receptors
- Orphan Nuclear Receptors
- Epigenetics and Nuclear Signaling
- Chromatin Modifying Enzymes
- Acetylation
- HDACs
- Class II / Hda1 Class
- Metabolism
- Pathways and Processes
- Metabolic signaling pathways
- Lipid and lipoprotein metabolism
- Cholesterol Metabolism
- Metabolism
- Pathways and Processes
- Metabolic signaling pathways
- Lipid and lipoprotein metabolism
- Lipoprotein metabolism
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab120354 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
| Application | Abreviews | Notes |
|---|---|---|
| Functional Studies |
Use at an assay dependent concentration.
|
| Notes |
|---|
|
Functional Studies
Use at an assay dependent concentration. |
Images
-
Chemical Structure - Flufenamic acid, COX inhibitor (ab120354)2D chemical structure image of ab120354, Flufenamic acid, COX inhibitor
-
Functional Studies - Flufenamic acid, COX inhibitor (ab120354)ab51110 staining AMPKα 1 + AMPKα 2 (phosphoT172) in HeLa cells treated with flufenamic acid (ab120354), by ICC/IF. Increase in AMPKα 1 + AMPKα 2 (phosphoT172) nuclear expression correlates with increased concentration of flufenamic acid, as described in literature.
The cells were incubated at 37°C for 30 minutes in media containing different concentrations of ab120354 (flufenamic acid) in DMSO, fixed with 4% formaldehyde for 10 minutes at room temperature and blocked with PBS containing 10% goat serum, 0.3 M glycine, 1% BSA and 0.1% tween for 2h at room temperature. Staining of the treated cells with ab51110 (5 µg/ml) was performed overnight at 4°C in PBS containing 1% BSA and 0.1% tween. A DyLight 488 goat anti-rabbit polyclonal antibody (ab96899) at 1/250 dilution was used as the secondary antibody.
Protocols
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
References (2)
ab120354 has been referenced in 2 publications.
- Sui S et al. iPSC-Derived Trabecular Meshwork Cells Stimulate Endogenous TM Cell Division Through Gap Junction in a Mouse Model of Glaucoma. Invest Ophthalmol Vis Sci 62:28 (2021). PubMed: 34427623
- Rhett JM et al. Connexin-Based Therapeutics and Tissue Engineering Approaches to the Amelioration of Chronic Pancreatitis and Type I Diabetes: Construction and Characterization of a Novel Prevascularized Bioartificial Pancreas. J Diabetes Res 2016:7262680 (2016). PubMed: 26788521